Rolapitant reduces nausea and vomiting associated with cisplatin-based chemotherapy

During a press conference at ESMO 2014, Dr Bernardo Leon Rapoport, The Medical Oncology Centre Rosebank, Johannesburg, South Africa, presents the results of a Phase III study on the use of rolapitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy.